New drug ZKLJ02 tested for safety in 50 healthy chinese adults

NCT ID NCT07638098

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tested a single dose of ZKLJ02 injection in 50 healthy Chinese adults to see if it is safe and how the body handles it. Participants received either the drug or a placebo by IV over 2 hours. The study measured side effects, drug levels in blood, and effects on blood clotting. No treatment benefit was expected since all participants were healthy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ZKLJ02 injection

What could go wrong

This is a very early Phase 1 safety study in healthy people, so it won't show if ZKLJ02 works for any disease. The results may not apply to patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EVALUATE THE SAFETY AND TOLERABILITY OF ZKLJ02 INJECTION IN HEALTHY CHINESE RESEARCH PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yunnan Zhongke Longjin Biotechnology Co.,Ltd.

    Kunming, Yunnan, China